BTK and Burkitt lymphoma: Ibrutinib and our compound PLS-123 are very potent Btk inhibitors, yet exhibit no inhibitory role towards Burkitt lymphoma and normal B cells, suggesting these compounds might not be efficient targeted approaches towards tonic BCR signaling and Btk is not essential for tonic BCR signaling.